CA2735138C - Screening methods for transfusion related acute lung injury (trali) - Google Patents

Screening methods for transfusion related acute lung injury (trali) Download PDF

Info

Publication number
CA2735138C
CA2735138C CA2735138A CA2735138A CA2735138C CA 2735138 C CA2735138 C CA 2735138C CA 2735138 A CA2735138 A CA 2735138A CA 2735138 A CA2735138 A CA 2735138A CA 2735138 C CA2735138 C CA 2735138C
Authority
CA
Canada
Prior art keywords
hna
trali
screening methods
lung injury
acute lung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2735138A
Other languages
English (en)
French (fr)
Other versions
CA2735138A1 (en
Inventor
Andreas Greinacher
Jan Wesche
Juergen Bux
Angelika Reil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Greifswald
DRK Blutspendedienst West gGmbH
Original Assignee
Ernst Moritz Arndt Universitaet Greifswald
DRK Blutspendedienst West gGmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ernst Moritz Arndt Universitaet Greifswald, DRK Blutspendedienst West gGmbH filed Critical Ernst Moritz Arndt Universitaet Greifswald
Publication of CA2735138A1 publication Critical patent/CA2735138A1/en
Application granted granted Critical
Publication of CA2735138C publication Critical patent/CA2735138C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2735138A 2008-09-04 2009-09-03 Screening methods for transfusion related acute lung injury (trali) Active CA2735138C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102008045696.9 2008-09-04
DE102008045696A DE102008045696A1 (de) 2008-09-04 2008-09-04 Granulozyten HNA-3a/b-Antigen
PCT/EP2009/006386 WO2010025915A1 (en) 2008-09-04 2009-09-03 Screening methods for transfusion related acute lung injury (trali)

Publications (2)

Publication Number Publication Date
CA2735138A1 CA2735138A1 (en) 2010-03-11
CA2735138C true CA2735138C (en) 2021-06-01

Family

ID=41266687

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2735138A Active CA2735138C (en) 2008-09-04 2009-09-03 Screening methods for transfusion related acute lung injury (trali)

Country Status (9)

Country Link
US (4) US8084216B2 (https=)
EP (1) EP2321644B1 (https=)
JP (1) JP5766606B2 (https=)
CN (1) CN102203609B (https=)
AU (2) AU2009289809B2 (https=)
BR (1) BRPI0918233B8 (https=)
CA (1) CA2735138C (https=)
DE (1) DE102008045696A1 (https=)
WO (1) WO2010025915A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2162792A4 (en) 2007-05-29 2011-08-24 Lab Partners Associates Inc SYSTEM AND METHOD FOR MAINTAINING FLASH CONTACT COMMUNICATIONS BETWEEN A CAMERA AND A WIRELESS DEVICE
WO2009114522A2 (en) * 2008-03-10 2009-09-17 Bonfils Blood Center Compositions, kits and methods for determining etiology of trali and detecting patients at risk for this transfusion reaction
DE102008045696A1 (de) * 2008-09-04 2010-03-11 Drk Blutspendedienst West Ggmbh Granulozyten HNA-3a/b-Antigen
WO2010059971A1 (en) * 2008-11-21 2010-05-27 Martin Heath Bluth Diagnosing and monitoring response to treatment of non-incontinent urological and related diseases
WO2010065425A1 (en) 2008-12-01 2010-06-10 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detection of complement fixing antibodies
US10101337B2 (en) 2013-03-14 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Methods of detecting donor-specific antibodies and systems for practicing the same
EP3140322B1 (en) * 2014-05-09 2021-02-17 One Lambda, Inc. Modified fc gamma receptor type iii (fc iii, hna-1) polypeptides and the uses thereof
US10527613B2 (en) 2015-11-10 2020-01-07 The Board Of Trustees Of The Leland Stanford Junior University Biomarker detection methods and systems and kits for practicing same
WO2017094733A1 (ja) * 2015-11-30 2017-06-08 日産化学工業株式会社 分子標的医薬に結合するｄｎａアプタマー及びそれを用いる分子標的医薬の検出方法
AU2016402264B2 (en) * 2016-04-15 2024-08-22 Pontificia Universidad Católica De Chile Pharmaceutical composition for reducing the symptoms and disease of the respiratory infection caused by human metapneumovirus (HMPV), which comprises at least one agent that neutralises the function of the TSLP and/or TSLPR and/or OX40L and/or CD177 molecules, and a pharmaceutically acceptable excipient, and the use thereof
CN116083551B (zh) * 2022-10-11 2025-02-21 南宁中心血站(南宁输血医学研究所) 用于检测人类中性粒细胞抗原基因分型的引物组合、试剂盒及方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US7411051B2 (en) 1997-03-07 2008-08-12 Human Genome Sciences, Inc. Antibodies to HDPPA04 polypeptide
US20030082646A1 (en) 1998-12-29 2003-05-01 The Regents Of The University Of Michigan Antigenic targets of autoimmune sensorineural hearing loss (AISNHL) and development of tests for diagnosis and management of AISNHL
CA2383592A1 (en) 1999-03-31 2000-10-05 Curagen Corporation 2384891 acids including open reading frames encoding polypeptides; orfx
US6943235B1 (en) 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
EP1074617A3 (en) 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
FR2800750B1 (fr) 1999-11-05 2003-01-31 Centre Nat Rech Scient Proteines membranaires ctl (choline transporter like) impliquees dans le transport de la choline
DE10028725B4 (de) 2000-06-09 2013-03-21 Jürgen Bux Primärstruktur des HNA-2a (ehemals NB1)-Antigens
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20030219777A1 (en) * 2001-12-18 2003-11-27 Lynx Therapeutics, Inc. Identification of candidate genes for the atherosclerosis susceptibility locus (ATHS)
US7829292B2 (en) 2002-05-06 2010-11-09 The Regents Of The University Of Michigan Compositions and methods for diagnosing, predicting therapeutic response of, and monitoring autoimmune disease
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
CA2516128A1 (en) * 2003-02-14 2004-09-02 Sagres Discovery, Inc. Therapeutic targets in cancer
US7303985B2 (en) 2003-11-17 2007-12-04 Intel Corporation Zeolite-carbon doped oxide composite low k dielectric
WO2007108368A1 (ja) * 2006-03-23 2007-09-27 Japanese Red Cross Society 顆粒球抗体の検出に用いられるパネル細胞
DE102008045696A1 (de) * 2008-09-04 2010-03-11 Drk Blutspendedienst West Ggmbh Granulozyten HNA-3a/b-Antigen

Also Published As

Publication number Publication date
US20150203915A1 (en) 2015-07-23
EP2321644B1 (en) 2016-12-14
JP2012501631A (ja) 2012-01-26
BRPI0918233B1 (pt) 2020-12-01
US20120070834A1 (en) 2012-03-22
CN102203609B (zh) 2017-07-11
US8084216B2 (en) 2011-12-27
US20100055706A1 (en) 2010-03-04
BRPI0918233A2 (pt) 2015-12-15
CA2735138A1 (en) 2010-03-11
CN102203609A (zh) 2011-09-28
WO2010025915A1 (en) 2010-03-11
AU2009289809A8 (en) 2011-05-12
US20130189696A1 (en) 2013-07-25
US8999651B2 (en) 2015-04-07
US8435733B2 (en) 2013-05-07
EP2321644A1 (en) 2011-05-18
BRPI0918233B8 (pt) 2021-07-27
US9963741B2 (en) 2018-05-08
AU2009289809A1 (en) 2010-03-11
AU2016204135A1 (en) 2016-07-14
AU2009289809B2 (en) 2016-07-07
JP5766606B2 (ja) 2015-08-19
DE102008045696A1 (de) 2010-03-11

Similar Documents

Publication Publication Date Title
CA2735138C (en) Screening methods for transfusion related acute lung injury (trali)
DE602007011937D1 (de) Peptidantikörperdepletion und anwendung zur probenvorbereitung für massenspektrometrie
US9068988B2 (en) Compositions and methods of detecting TIABs
EP3275901A8 (en) Human embryonic stem cell methods and podxl expression
WO2007064917A3 (en) Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
SI2183599T1 (sl) Visoko občutljiv imunološki preskus in komplet za določanje peptidov in proteinov biološkega interesa
EP2667194A3 (en) Ratio based biomarkers and methods of use thereof
WO2008027942A3 (en) Combination hepatitis c virus antigen and antibody detection method
EP3196213A3 (en) Antibodies directed to her-3 and uses thereof
MX2009013824A (es) Proteinas de enlace de antigeno que enlazan par-2.
EP2295465A3 (en) Human monoclonal antibodies to influenza M2 protein and methods of making and using same
WO2006124641A3 (en) Anti-mesothelin antibodies useful for immunological assays
EP1918302A3 (en) Methods for the identification and the isolation of epitope specific antibodies
BR112013016495A2 (pt) anticorpo monoclonal que reconhece a proteína l2 do papilomavírus humano (hpv) e método para medir o título de anticorpo que neutraliza o hpv usando a mesma
WO2005095461A3 (en) Gold-binding protein and use thereof
WO2005103074A3 (en) Combinatorial protein library screening by periplasmic expression
WO2006034278A3 (en) Methods and compositions for detecting cancer using components of the u2 spliceosomal particle
WO2012126118A8 (en) Polypeptides with affinity for heat shock proteins (hsps) and hsp associated complexes (hacs) and their use in diagnosis and therapy
WO2006069203A3 (en) Methods for proteomic profiling using non-natural amino acids
WO2007090630A3 (en) Peptide aptamer for neutralizing the binding of platelet antigene specific antibodies and diagnostic and therapeutic applications containing the same
WO2009074318A3 (en) Novel rubella e1 envelope protein variants and their use in the detection of anti-rubella antibodies
WO2005019831A3 (en) Methods for reducing complexity of a sample using small epitope antibodies
WO2007046891A3 (en) Systems and methods for separating proteins from connective tissue
WO2009151697A3 (en) Compositions and processes relating to human bocavirus
WO2005044989A3 (en) Polynucleotides and polypeptides of anaplasma phagocytophilum and methods of using the same

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140903

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240829

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240829

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240829

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250821

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250821